BioCentury
ARTICLE | Clinical News

Bristol-Myers reports data for anti-PD-L1 mAb

June 5, 2012 12:47 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) reported data from 160 evaluable patients with advanced solid tumors in the Phase I MDX1105-01 trial of BMS-936559, a human mAb against programmed cell death 1 ligand 1 ( CD274 molecule; PD-L1; B7-H1). Objective responses were seen in nine (17%) of 52 melanoma patients, five (10%) of 49 of non-small cell lung cancer (NSCLC) patients, one (6%) of 17 ovarian cancer patients and two (12%) of 17 renal cell carcinoma (RCC) patients. There were no objective responses in patients with colorectal or pancreatic cancer. Stable disease for at least 24 weeks was seen in 14 (27%) melanoma patients, six (12%) NSCLC patients, three (18%) ovarian cancer patients and seven (41%) RCC patients. ...